HK1102563A1 - Stabilized interferon liquid formulations - Google Patents
Stabilized interferon liquid formulationsInfo
- Publication number
- HK1102563A1 HK1102563A1 HK07110897.6A HK07110897A HK1102563A1 HK 1102563 A1 HK1102563 A1 HK 1102563A1 HK 07110897 A HK07110897 A HK 07110897A HK 1102563 A1 HK1102563 A1 HK 1102563A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- liquid formulations
- stabilized interferon
- interferon liquid
- stabilized
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04076626 | 2004-06-01 | ||
US61637804P | 2004-10-06 | 2004-10-06 | |
PCT/EP2005/052414 WO2005117949A1 (en) | 2004-06-01 | 2005-05-27 | Stabilized interferon liquid formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1102563A1 true HK1102563A1 (en) | 2007-11-30 |
Family
ID=34928261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07110897.6A HK1102563A1 (en) | 2004-06-01 | 2007-10-09 | Stabilized interferon liquid formulations |
Country Status (15)
Country | Link |
---|---|
US (1) | US7731948B2 (es) |
EP (1) | EP1750751B1 (es) |
JP (1) | JP4988562B2 (es) |
CN (1) | CN1993139B (es) |
AU (1) | AU2005249233B2 (es) |
BR (1) | BRPI0510526A (es) |
CA (1) | CA2567310A1 (es) |
EA (1) | EA010979B1 (es) |
ES (1) | ES2418833T3 (es) |
HK (1) | HK1102563A1 (es) |
IL (1) | IL179620A (es) |
MX (1) | MXPA06014078A (es) |
NO (1) | NO20065860L (es) |
UA (1) | UA92146C2 (es) |
WO (1) | WO2005117949A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4658961B2 (ja) | 2003-12-11 | 2011-03-23 | アレス トレーディング エス.エー. | 安定化されたインターフェロン液体製剤 |
US7879320B2 (en) | 2004-05-17 | 2011-02-01 | Ares Trading S.A. | Hydrogel interferon formulations |
CA2571800A1 (en) * | 2005-12-23 | 2007-06-23 | Canadian Blood Services | Nitrophenyls and related compounds and thimerosal for the inhibition of immune related cell or tissue destruction |
TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
WO2008066322A1 (en) * | 2006-11-28 | 2008-06-05 | Daewoong Co., Ltd. | A stable hsa-free and antioxidant-free pharmaceutical composition comprising interferon-beta |
AU2008269086B2 (en) | 2007-06-25 | 2014-06-12 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
WO2009080699A2 (en) * | 2007-12-20 | 2009-07-02 | Merck Serono S.A. | Peg-interferon-beta formulations |
US9956165B2 (en) * | 2010-03-01 | 2018-05-01 | Cytodyn Inc. | Concentrated protein formulations and uses thereof |
US20120269770A1 (en) * | 2010-11-22 | 2012-10-25 | Mark Brader | Stable Preserved Compositions of Interferon-Beta |
MX359947B (es) * | 2011-03-15 | 2018-10-17 | Biogen Ma Inc | EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE. |
RU2527701C1 (ru) * | 2013-05-24 | 2014-09-10 | Федеральное государственное бюджетное учреждение "Научный центр реконструктивной и восстановительной хирургии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НЦРВХ" СО РАМН) | Способ приготовления средства, обладающего свойством стимуляции регенерации хрящевой, костной, мышечной тканей и способ стимуляции регенерации хрящевой, костной, мышечной тканей с использованием приготовленного средства |
EP3126379B1 (en) * | 2014-04-04 | 2019-05-22 | Ares Trading SA | Novel ifn beta protein analogs |
US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9744239B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
CN114053397B (zh) * | 2022-01-17 | 2022-12-20 | 北京三元基因药业股份有限公司 | 一种稳定的干扰素多剂量注射液及其制备方法 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4469228A (en) | 1983-05-31 | 1984-09-04 | Schering Corporation | Interferon kit |
US4636383A (en) | 1984-08-29 | 1987-01-13 | Schering Corporation | Interferon-cyclaradine combination |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
US4879111A (en) | 1986-04-17 | 1989-11-07 | Cetus Corporation | Treatment of infections with lymphokines |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
IT1244511B (it) | 1991-04-15 | 1994-07-15 | Isi Ist Sierovaccinogeno Ital | Idrogeli a base di policarbossilati sintetici e proteine per il rilascio controllato di farmaci e procedimento per la loro preparazione. |
KR960009385B1 (en) * | 1993-11-24 | 1996-07-18 | Samsung Bp Chemicals Co Ltd | Apparatus and method for wastewater treatment by activated sludge process type |
IT1272252B (it) | 1994-05-16 | 1997-06-16 | Applied Research Systems | Formulazioni liquide di interferone beta |
TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
US5858001A (en) | 1995-12-11 | 1999-01-12 | Elan Medical Technologies Limited | Cartridge-based drug delivery device |
AU739469B2 (en) | 1996-12-20 | 2001-10-11 | Alza Corporation | Gel composition and methods |
US6013253A (en) | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
PT1224940E (pt) | 1997-09-23 | 2005-01-31 | Rentschler Biotech Gmbh | Formulacoes liquidas de intrferao beta |
JP2001526033A (ja) * | 1997-12-08 | 2001-12-18 | ジェネンテク・インコーポレイテッド | ヒトインターフェロン−イプシロンというi型インターフェロン |
CN1187094C (zh) | 1998-04-28 | 2005-02-02 | 应用研究系统Ars股份公司 | 多元醇干扰素β偶联物 |
US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
NZ517184A (en) | 1999-07-13 | 2004-02-27 | Bolder Biotechnology Inc | Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain |
US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
HUP0203133A3 (en) * | 1999-10-04 | 2005-07-28 | Chiron Corp Emeryville | Stabilized liquid polypeptide-containing pharmaceutical compositions |
CN1175901C (zh) * | 1999-12-06 | 2004-11-17 | 天津华立达生物工程有限公司 | 一种稳定的干扰素水溶液 |
US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
US6586785B2 (en) | 2000-06-29 | 2003-07-01 | California Institute Of Technology | Aerosol silicon nanoparticles for use in semiconductor device fabrication |
KR100396983B1 (ko) | 2000-07-29 | 2003-09-02 | 이강춘 | 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체 |
DE60130580T2 (de) | 2000-12-27 | 2008-06-12 | Ares Trading S.A. | Lipidmikropartikel mittels kryogenischer mikronisierung |
US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
EP1471891A4 (en) | 2002-02-08 | 2007-04-11 | Alkermes Inc | POLYMER-BASED COMPOSITIONS FOR PROLONGED RELEASE |
US20040037809A1 (en) | 2002-06-28 | 2004-02-26 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon beta |
TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
AR044302A1 (es) | 2003-05-13 | 2005-09-07 | Ares Trading Sa | Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos |
US7879320B2 (en) | 2004-05-17 | 2011-02-01 | Ares Trading S.A. | Hydrogel interferon formulations |
-
2005
- 2005-05-27 EA EA200602257A patent/EA010979B1/ru not_active IP Right Cessation
- 2005-05-27 EP EP05752765.7A patent/EP1750751B1/en active Active
- 2005-05-27 BR BRPI0510526-9A patent/BRPI0510526A/pt not_active IP Right Cessation
- 2005-05-27 MX MXPA06014078A patent/MXPA06014078A/es active IP Right Grant
- 2005-05-27 CA CA002567310A patent/CA2567310A1/en not_active Withdrawn
- 2005-05-27 AU AU2005249233A patent/AU2005249233B2/en active Active
- 2005-05-27 WO PCT/EP2005/052414 patent/WO2005117949A1/en active Application Filing
- 2005-05-27 US US11/597,987 patent/US7731948B2/en active Active
- 2005-05-27 UA UAA200612406A patent/UA92146C2/ru unknown
- 2005-05-27 CN CN2005800257255A patent/CN1993139B/zh active Active
- 2005-05-27 ES ES05752765T patent/ES2418833T3/es active Active
- 2005-05-27 JP JP2007513938A patent/JP4988562B2/ja active Active
-
2006
- 2006-11-27 IL IL179620A patent/IL179620A/en not_active IP Right Cessation
- 2006-12-19 NO NO20065860A patent/NO20065860L/no not_active Application Discontinuation
-
2007
- 2007-10-09 HK HK07110897.6A patent/HK1102563A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN1993139B (zh) | 2011-02-16 |
JP2008500996A (ja) | 2008-01-17 |
US20070292391A1 (en) | 2007-12-20 |
AU2005249233A1 (en) | 2005-12-15 |
WO2005117949A1 (en) | 2005-12-15 |
IL179620A0 (en) | 2007-05-15 |
US7731948B2 (en) | 2010-06-08 |
UA92146C2 (ru) | 2010-10-11 |
IL179620A (en) | 2013-04-30 |
AU2005249233B2 (en) | 2010-10-07 |
CN1993139A (zh) | 2007-07-04 |
JP4988562B2 (ja) | 2012-08-01 |
ES2418833T3 (es) | 2013-08-16 |
EA010979B1 (ru) | 2008-12-30 |
EA200602257A1 (ru) | 2007-04-27 |
EP1750751A1 (en) | 2007-02-14 |
EP1750751B1 (en) | 2013-04-10 |
CA2567310A1 (en) | 2005-12-15 |
BRPI0510526A (pt) | 2007-10-30 |
MXPA06014078A (es) | 2007-02-15 |
NO20065860L (no) | 2006-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1102563A1 (en) | Stabilized interferon liquid formulations | |
ZA200706256B (en) | Stabilized liquid polypeptide formulations | |
IL181265A0 (en) | Stabilizing formulations | |
IL177566A0 (en) | Pharmaceutical formulations | |
IL188915A0 (en) | Liquid formulations | |
EP1773871A4 (en) | COMPOUNDS ASSOCIATED WITH TISSUE DIFFERENTIATION FACTOR AND THEIR ANALOGUES | |
GB0426301D0 (en) | Pharmaceutical formulations | |
GB0423565D0 (en) | Formulation | |
GB0412530D0 (en) | Formulation | |
HK1097751A1 (en) | Acyclovir formulations | |
EP1764102A4 (en) | MEDICINAL COMPOSITION CONTAINING QUINOLONE | |
GB0416397D0 (en) | Pharmaceutical formulations | |
EP1951258A4 (en) | LIQUID FORMULATIONS | |
GB0506035D0 (en) | Improved formulation | |
GB0403769D0 (en) | Liquid composition | |
GB0417226D0 (en) | Formulations | |
GB0417248D0 (en) | Formulations | |
IL179208A0 (en) | Intereferon formulations | |
GB0426295D0 (en) | Novel formulations | |
GB0420821D0 (en) | Novel formulations | |
GB0426292D0 (en) | Novel formulations | |
GB0420817D0 (en) | Novel formulations | |
GB0420820D0 (en) | Novel formulations | |
GB0426296D0 (en) | Novel formulations | |
GB0427244D0 (en) | Novel formulations |